Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/4 cls
Amgen (NASDAQ:AMGN) Lazard Joel Sendek Upgrade Hold (from sell) -5% $44.80
Sendek sees the stock as fairly valued at $46, a five-year low. Still, he expects Amgen to report disappointing 4Q07 earnings and FDA's Oncologic Drugs Advisory Committee (ODAC) to place further restrictions on erythropoiesis-stimulating agents (ESAs) at its meeting in 1Q08, which could lead to more share price deterioration. Amgen markets two ESAs: Aranesp darbepoetin alfa for cancer and renal indications, and Epogen epoetin alfa for chronic renal failure.
CombinatoRx (NASDAQ:CRXX) Piper Jaffray Edward

Read the full 988 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers